ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1394

Nationwide Retrospective Cohort Study on Clinical Outcomes in Rheumatoid Arthritis Patients Treated with JAK Inhibitors

Yurilu Gonzalez Moret1, Diego Lema2 and Fabian Rodriguez Quinonez3, 1Jefferson Einstein Hospital, Philadelphia, PA, 2Universidad Central de Venezuela, University of Wisconsin, Philadelphia, PA, 3Einstein Medical Center Philadelphia, Philadelphia, PA

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, Outcome measures, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: RA – Treatment Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Janus kinase inhibitors (JAKi) are a class of disease activity-modifying drugs (DMARDs) that have quickly established a role in managing rheumatoid arthritis. Inhibition of the JAK/STAT pathway makes them potent immunosuppressants with comparable efficacy to antibodies and other biologicals. However, this mechanism of action has been linked to several adverse effects, including infection, bowel perforation, and cardiovascular events. We investigated the association between JAKi use and major adverse events leveraging the large TriNetX database.

Methods: This is a nationwide, retrospective study. We used the global, multicenter research network (TriNetX) database from 89 large healthcare organizations across multiple countries. We included patients over 18 years with RA diagnosed between January 1, 2020, and June 9, 2024, using ICD-10 and ICD-9 codes. Patients were compared based on the use of JAKi (tofacitinib or baricitinib or upadacitinib) using 1:1 propensity score matching. Matching accounted for demographics (age at diagnosis, race, and gender), chronic associated comorbidities, risk factors for bowel perforation (history of peptic ulcer disease, prior malignancies of the colon, inflammatory bowel disease, diverticulosis), immunosuppressant use and laboratory values at baseline. Outcomes included non-traumatic bowel perforation, general infections, major cardiovascular events (MACE), and venous thromboembolic events (VTE). Exposure for outcomes was anytime post-index event, excluding patients with pre-index event outcomes. Risk ratios (RR) with 95% confidence intervals were calculated for each outcome, with a p-value < 0.05 considered significant.

Results: We identified 21,621 RA patients on JAKi and 493,879 RA patients not on JAKi. The mean age at diagnosis was 57.2 ± 13.7 for patients on JAKi and 61.2 ± 15.3 years for patients not on JAKi. In both groups of RA patients, females (76.9% and 71.4%) and Caucasians (69.1% and 63.7%) were the most common gender and race, respectively. Comorbidities like (hypertension, type 2 diabetes, hyperlipidemia, diverticular disease, and neoplasms of the colon) were more common in RA patients not on JAKi. Conversely, JAKi users were more frequently obese smokers, had a higher use of immunosuppressant medications, and higher levels of C-reactive protein (CRP) and rheumatoid factor (RF) at baseline. After matching, RA patients on JAKi had lower risk of bowel perforation (RR=0.89, CI95% 0.79, 0.99; p=0.04), general infections (RR= 0.93, CI95% 0.88,0.97; p=0.006), and MACE (RR= 0.76, CI95% 0.68,0.85; p< 0.001) compared to RA patients not on JAKi. No significant risk difference was found in VTE events between groups.

Conclusion: In this nationwide retrospective study, we found that RA patients on JAKi had reduced risk of bowel perforation, general infections, and MACE- a surprising finding contrary to most reported literature. While no mechanistic explanation can be determined from our study design, we hypothesize that JAK/STAT inhibition compares favorably to other immunosuppressants and treatments for patients not on JAKi, including NSAIDs.

Supporting image 1

Table 1. Baseline Patient Characteristics of Study groups, Before Propensity Score Matching  

Supporting image 2

Table 2. Outcomes of patients with rheumatoid arthritis grouped by JAK kinase inhibitor use


Disclosures: Y. Gonzalez Moret: None; D. Lema: None; F. Rodriguez Quinonez: None.

To cite this abstract in AMA style:

Gonzalez Moret Y, Lema D, Rodriguez Quinonez F. Nationwide Retrospective Cohort Study on Clinical Outcomes in Rheumatoid Arthritis Patients Treated with JAK Inhibitors [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/nationwide-retrospective-cohort-study-on-clinical-outcomes-in-rheumatoid-arthritis-patients-treated-with-jak-inhibitors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nationwide-retrospective-cohort-study-on-clinical-outcomes-in-rheumatoid-arthritis-patients-treated-with-jak-inhibitors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology